ORCHID PHARMA GETS SHARED 180-DAY EXCLUSIVITY RIGHTS FOR PARKINSON'S DRUG IN US

摘要

This was possible after the company received final approval for the drug, rasagiline mesylate tablets (0.5 mg and 1 mg), from US drug regulator Orchid Pharma Ltd (formerly known as Orchid Chemicals & Pharmaceuticals Ltd) has received final approval from the US Food & Drug Administration (FDA) for its rasagilinetablets 0.5 mg and 1 mg, with 180-day shared exclusivity for the company. Orchid Pharma expects to launch rasagiline mesylate tablets, which are indicated for treatment of signs and symptoms of idiopathic Parkinson's disease, in Q4 of FY16-17.